SUPN - Supernus Pharmaceuticals reports Q4 results sees FY 2023 revenue in-line February, 28 2023 04:27 PM Supernus Pharmaceuticals Inc. Supernus Pharmaceuticals press release ( NASDAQ: SUPN ): Q4 GAAP EPS of $0.43. Revenue of $167.33M (+5.2% Y/Y). Sees FY 2023 revenue of $580M to $620M. The consensus estimate is $601.21M. For further details see: Supernus Pharmaceuticals reports Q4 results, sees FY 2023 revenue in-line